Jones Hill Capital LP
Sector Allocation
- Healthcare100.0%$470.4M
AUM History
13fpro.ai/research/fund/jones-hill-capital-lp-2102314
Largest positions — Q2 2026
BMRN
$81.9MGILD
$43.3MARQT
$28.6MMDGL
$28.2MBCAX
$26.5MRLMD
$25.3MTRVI
$25.0MPHVS
$23.4MXENE
$22.2MANIP
$19.4MIMCR
$16.3MAMLX
$16.1MINSM
$13.0MNUVL
$12.2MCAPR
$10.1MACRS
$9.3MIMUX
$8.3MORIC
$8.1MTNXP
$8.0MSNDX
$7.4M
Top 20 stock positions. Options are left out: 13F reports them at the underlying's value.
13fpro.ai/research/fund/jones-hill-capital-lp-2102314
Jones Hill Capital LP 13F holdings — Q2 2026
$470.4M portfolio (+0.8% QoQ) · 29 holdings · Q2 2026 13F · top 10 are 69% of the stock portfolio
$81.9M
17.4% of stocks
+13%This quarter-18.6%Since filed2+ qtrsHeld$43.3M
9.2% of stocks
NewThis quarter+14.9%Since filedNew this quarterHeld$28.6M
6.1% of stocks
NewThis quarter+23.1%Since filedNew this quarterHeld$28.2M
6.0% of stocks
NewThis quarter-13.7%Since filedNew this quarterHeld$26.5M
5.6% of stocks
-29%This quarter-28.5%Since filed2+ qtrsHeld$25.3M
5.4% of stocks
+966%This quarter-32.0%Since filed2+ qtrsHeld$25.0M
5.3% of stocks
+262%This quarter-31.1%Since filed2+ qtrsHeld$23.4M
5.0% of stocks
+306%This quarter-7.3%Since filed2+ qtrsHeld$22.2M
4.7% of stocks
NewThis quarter-44.3%Since filedNew this quarterHeld$19.4M
4.1% of stocks
-27%This quarter-2.9%Since filed2+ qtrsHeld
All holdings — Jones Hill Capital LP (Q2 2026)
29 disclosed positions from the Form 13F-HR on SEC EDGAR, with quarter-over-quarter share changes. Largest by value first; the ten above are not repeated.
| # | Company | Held | Source | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 11 | Immunocore Holdings plcadr | Healthcare | $16.3M | 3.5% | 513K | New | 1 qtr | AI quality score is Pro: unlock with a free trial | 13F | |
| 12 | Amylyx Pharmaceuticals, Inc. | Healthcare | $16.1M | 3.4% | 894K | -44% | 2+ qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 13 | INSMED Inc | Healthcare | $13.0M | 2.8% | 122K | New | 1 qtr | AI quality score is Pro: unlock with a free trial | 13F | |
| 14 | Nuvalent, Inc. | Healthcare | $12.2M | 2.6% | 98K | -67% | 2+ qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 15 | CAPRICOR THERAPEUTICS, INC. | Healthcare | $10.1M | 2.1% | 421K | -54% | 2+ qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 16 | Aclaris Therapeutics, Inc. | Healthcare | $9.3M | 2.0% | 1.76M | New | 1 qtr | AI quality score is Pro: unlock with a free trial | 13F | |
| 17 | IMMUNIC, INC. | Healthcare | $8.3M | 1.8% | 540K | New | 1 qtr | AI quality score is Pro: unlock with a free trial | 13F | |
| 18 | Oric Pharmaceuticals, Inc. | Healthcare | $8.1M | 1.7% | 747K | New | 1 qtr | AI quality score is Pro: unlock with a free trial | 13F | |
| 19 | Tonix Pharmaceuticals Holding Corp. | Healthcare | $8.0M | 1.7% | 625K | +38% | 2+ qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 20 | Syndax Pharmaceuticals Inc | Healthcare | $7.4M | 1.6% | 340K | New | 1 qtr | AI quality score is Pro: unlock with a free trial | 13F | |
| 21 | Olema Pharmaceuticals, Inc. | Healthcare | $7.2M | 1.5% | 574K | New | 1 qtr | AI quality score is Pro: unlock with a free trial | 13F | |
| 22 | Vir Biotechnology, Inc. | Healthcare | $6.7M | 1.4% | 659K | -45% | 2+ qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 23 | Corbus Pharmaceuticals Holdings, Inc. | Healthcare | $6.1M | 1.3% | 654K | New | 1 qtr | AI quality score is Pro: unlock with a free trial | 13F | |
| 24 | Dianthus Therapeutics, Inc. /DE/ | Healthcare | $5.6M | 1.2% | 57K | New | 1 qtr | AI quality score is Pro: unlock with a free trial | 13F | |
| 25 | VERTEX PHARMACEUTICALS INC / MA | Healthcare | $5.5M | 1.2% | 11K | -90% | 2+ qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 26 | $ELVN | Enliven Therapeutics, Inc. | Healthcare | $2.5M | 0.5% | 50K | -92% | |||
| 27 | $GPCR | Structure Therapeutics Inc. | Healthcare | $2.2M | 0.5% | 41K | -60% | |||
| 28 | $PHAT | Phathom Pharmaceuticals, Inc. | Healthcare | $1.8M | 0.4% | 161K | New | |||
| 29 | $ACHV | ACHIEVE LIFE SCIENCES, INC. | Healthcare | $175K | 0.0% | 27K | New |
What changed in Q2 2026
Against the previous quarter's 13F: 15 new, 5 added to, 9 trimmed, 12 sold out. Share-count changes; largest moves by dollar size first.
New positions (15)
$GILDGILEAD SCIENCES, INC.$43.3M
first bought this quarter
$ARQTArcutis Biotherapeutics, Inc.$28.6M
first bought this quarter
$MDGLMADRIGAL PHARMACEUTICALS, INC.$28.2M
first bought this quarter
$XENEXenon Pharmaceuticals Inc.$22.2M
first bought this quarter
$IMCRImmunocore Holdings plc$16.3M
first bought this quarter
$INSMINSMED Inc$13.0M
first bought this quarter
+9 more in the Excel export
Added to (5)
Trimmed (9)
$VRTXVERTEX PHARMACEUTICALS INC / MA-90%
now $5.5M · held 2+ qtrs
$ELVNEnliven Therapeutics, Inc.-92%
now $2.5M · held 2+ qtrs
$NUVLNuvalent, Inc.-67%
now $12.2M · held 2+ qtrs
$AMLXAmylyx Pharmaceuticals, Inc.-44%
now $16.1M · held 2+ qtrs
$CAPRCAPRICOR THERAPEUTICS, INC.-54%
now $10.1M · held 2+ qtrs
$BCAXBicara Therapeutics Inc.-29%
now $26.5M · held 2+ qtrs
+3 more in the Excel export
Sold out (12)
$PCVXVaxcyte, Inc.was $37.5M
held 1+ qtrs
$TERNTerns Pharmaceuticals, Inc.was $27.5M
held 1+ qtrs
$RAREUltragenyx Pharmaceutical Inc.was $24.4M
held 1+ qtrs
$ARGXARGENX SEwas $19.0M
held 1+ qtrs
$FULCFulcrum Therapeutics, Inc.was $13.6M
held 1+ qtrs
$NUVBNuvation Bio Inc.was $10.2M
+6 more in the Excel export
Holdings by quarter
Every 13F Jones Hill Capital LP has filed, 1 earlier quarter. Pick one to see what it held then.
Is it too late to follow Jones Hill Capital?
Q2 2026 13F filed with the SEC on Aug 13, 2026. Prices are closing prices as of Oct 26, 2026.
Average quality of Jones Hill Capital's top 20 holdings: 47/100 (our AI quality score, weighted by position size; 12 of the 20 are scored)
Top 10 since filing
-12.9%
Value-weighted move of the 10 largest stock positions
Turnover
59%
Last quarter
Top 10 weight
69%
Share of the stock portfolio in its 10 largest positions
Held 4+ quarters
0%
Share of portfolio value in positions held a year or more
Highest-quality names it owns(among its 100 largest positions)
The 8 highest-scoring companies in this portfolio are a Pro feature.
How these are measured
- Moves since the quarter-end and since the filing date use our own daily closing prices, from the close on (or just before) each date to the latest close.
- Turnover is the lesser of shares bought or sold in a quarter, valued at the quarter-end prices in the 13F, divided by the average of the two quarters' stock portfolio values.
- Quarters held and add/trim streaks count back only through quarters whose filed holdings add up to the filing's own cover-page total (back to Q1 2026 for this fund). A change counts as an add or a trim when the split-adjusted share count moves by more than 1%.
- Estimate, not the fund's reported cost. For each quarter in the current holding period in which the fund's share count rose (split-adjusted), we take that quarter's average daily close and weight it by the shares added; sales do not change an average cost. Quarters where the stock's price history and the 13F's own implied price disagree by more than 2x are left out.
- Put and call option rows report the value of the underlying shares, not a position the fund paid for, so they are left out of all of the above.
Portfolio Overview
Jones Hill Capital LP disclosed 29 positions worth $470.4M in its Form 13F-HR for Q2 2026, led by $BMRN (BIOMARIN PHARMACEUTICAL INC) at 17.4% of the equity portfolio, followed by $GILD and $ARQT. During the quarter the fund opened 15 new positions and exited 12 — including a new stake in $GILD and a full exit from $PCVX. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from Jones Hill Capital LP’s Form 13F-HR filing with the SEC under CIK 2102314.
Funds like this
managers whose biggest positions overlap Jones Hill Capital'sBrowse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
AI-Powered Hedge Fund Analysis: Jones Hill Capital LP
13F Pro is an AI hedge fund tracker and stock research platform. For Jones Hill Capital LP (SEC CIK: 2102314), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Jones Hill Capital LP's portfolio is scored on an AI quality ranking built from its SEC filings (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.